Comparison of response evaluation with EORTC criteria and PERCIST in breast cancer
10.3760/cma.j.cn321828-20190808-00163
- VernacularTitle:EORTC标准和PERCIST在乳腺癌疗效评估中的应用比较
- Author:
Weiling LIAN
1
;
Zhongyi YANG
;
Mingwei WANG
;
Shaoli SONG
Author Information
1. 复旦大学附属肿瘤医院核医学科、复旦大学上海医学院肿瘤学系 200032
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2020;40(10):625-628
- CountryChina
- Language:Chinese
-
Abstract:
Response assessment in breast cancer by 18F-fluorodeoxyglucose (FDG) PET/CT can measure breast cancer cell glucose metabolic level. The evaluation criteria mainly include the European Organization for Research and Treatment of Cancer (EORTC) criteria and PET response evaluation criteria in solid tumors (PERCIST). This review describes and compares the methods and clinical applications of EORTC criteria and PERCIST in response assessment among patients with locally advanced breast cancer after neoadjuvant chemotherapy and recurrent and (or) metastatic breast cancer after systematic therapy.
